HRP20090112T3 - Derivati 2-(1 h-indonilsulfanil)-arila za primjenu u liječenju afektivnih poremećaja, bolova, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije - Google Patents

Derivati 2-(1 h-indonilsulfanil)-arila za primjenu u liječenju afektivnih poremećaja, bolova, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije

Info

Publication number
HRP20090112T3
HRP20090112T3 HR20090112T HRP20090112T HRP20090112T3 HR P20090112 T3 HRP20090112 T3 HR P20090112T3 HR 20090112 T HR20090112 T HR 20090112T HR P20090112 T HRP20090112 T HR P20090112T HR P20090112 T3 HRP20090112 T3 HR P20090112T3
Authority
HR
Croatia
Prior art keywords
alk
halo
cycloalk
ylsulfanyl
ylsulfonyl
Prior art date
Application number
HR20090112T
Other languages
English (en)
Inventor
Kehler Jan
Kroll Friedrich
Juhl Karsten
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20090112T3 publication Critical patent/HRP20090112T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Spoj naznačen time što ima opću formulu I kao njegova slobodna baza ili soligdjeisprekidana linija predstavlja izbornu vezu; isvaki od R1-R4 je nezavisno izabran iz grupe koju čine vodik, halogen, cijano, nitro, C1-6alk(en/in)il, C3-8-cikloalk(en)il, C3-8-cikloalk(en)il-C1-6-alk(en/in)il, amino, C1-6-alk(en/in)ilamino, di-(C1-6-alk(en/in)il)amino, C1-6-alk(en/in)ilkarbonil, aminokarbonil, C1-6-alk(en/in)ilaminokarbonil, di-(C1-6-alk(en)il)aminokarbonil, hidroksi, C1-6-alk(en/in)iloksi, C1-6-alk(en/in)ilsulfanil, halo-C1-6-alk(en/in)il, halo-C1-6-alk(en/in)ilsulfonil, halo-C1-6-alk(en/in)ilsulfanil i C1-6-alk(en/in)ilsulfonil; iR5 je izabran iz grupe koju čine vodik, halogen, cijano, C1-6-alk(en/in)il, C3-8-cikloalk(en)il, C3-8-cikloalk(en)il-C1-6-alk(en/in)il, amino, C1-6-alk(en/in)ilamino, di-(C1-6-alk(en/in)il)amino, C1-6alk(en/in)ilkarbonil, aminokarbonil, C1-6-alk(en/in)ilaminokarbonil, di-(C1-6-alk(en)il)aminokarbonil, hidroksi, C1-6-alk(en/in)iloksi, C1-6-alk(en/in)ilsulfanil, halo-C1-6-alk(en/in)il, halo-C1-6-alk(en/in)ilsulfonil, halo-C1-6-alk(en/in)ilsulfanil i C1-6-alk(en/in)ilsulfonil; isvaki od R6-R9 je nezavisno izabran iz grupe koju čine vodik, halogen, cijano, nitro, C1-6-alk(en/in)il, C3-8-cikloalk(en)il, C3-8-cikloalk(en)il-C1-6-alk(en/in)il, amino, C1-6-alk(en/in)ilamino, di-(C1-6-alk(en/in)il)amino, C1-6-alk(en/in)ilkarbonil, aminokarbonil, C1-6-alk(en/in)ilaminokarbonil, di-(C1-6-alk(en)il)aminokarbonil, hidroksi, C1-6-alk(en/in)iloksi, C1-6-alk(en/in)ilsulfanil, halo-C1-6-alk(en/in)il, halo-C1-6-alk(en/in)ilsulfonil, halo-C1-6-alk(en/in)ilsulfanil, C1-6-alk(en/in)ilsulfonil i C1-6-ak(en/in)il-O-CO-;iR10 je izabran iz grupe koju čine vodik, C1-6-alk(en/in)il, C3-8-cikloalk(en)il i C3-8-cikloalk(en)il-C1-6-alk(en/in)il; iZ je izabran iz grupe koju čine N, CH i C, uz uvjet da isprekidana linija predstavlja vezu kada je Z jednako C i isprekidana linija ne predstavlja vezu kada je Z jednako CH ili N. Patent sadrži još 24 patentna zahtjeva.
HR20090112T 2004-07-16 2009-02-23 Derivati 2-(1 h-indonilsulfanil)-arila za primjenu u liječenju afektivnih poremećaja, bolova, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije HRP20090112T3 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58855504P 2004-07-16 2004-07-16
DKPA200401121 2004-07-16
US69173605P 2005-06-17 2005-06-17
DKPA200500893 2005-06-17
PCT/DK2005/000491 WO2006007843A1 (en) 2004-07-16 2005-07-13 2-(1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence

Publications (1)

Publication Number Publication Date
HRP20090112T3 true HRP20090112T3 (hr) 2009-03-31

Family

ID=39243745

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090112T HRP20090112T3 (hr) 2004-07-16 2009-02-23 Derivati 2-(1 h-indonilsulfanil)-arila za primjenu u liječenju afektivnih poremećaja, bolova, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije

Country Status (26)

Country Link
US (1) US7678800B2 (hr)
EP (1) EP1771415B1 (hr)
JP (1) JP4865710B2 (hr)
KR (1) KR20070036061A (hr)
CN (1) CN1972911A (hr)
AR (1) AR052308A1 (hr)
AT (1) ATE420071T1 (hr)
AU (1) AU2005263324A1 (hr)
BR (1) BRPI0512073A (hr)
CA (1) CA2570805C (hr)
CY (1) CY1108942T1 (hr)
DE (1) DE602005012272D1 (hr)
DK (1) DK1771415T3 (hr)
EA (1) EA011418B1 (hr)
ES (1) ES2317266T3 (hr)
HR (1) HRP20090112T3 (hr)
IL (1) IL179924A0 (hr)
MX (1) MXPA06015201A (hr)
NO (1) NO20066010L (hr)
PL (1) PL1771415T3 (hr)
PT (1) PT1771415E (hr)
RS (1) RS50804B (hr)
SI (1) SI1771415T1 (hr)
UA (1) UA82610C2 (hr)
WO (1) WO2006007843A1 (hr)
ZA (1) ZA200610162B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
US20110137063A1 (en) * 2008-07-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
JP2016537171A (ja) * 2013-11-14 2016-12-01 カリフォルニア インスティチュート オブ テクノロジー 調節性眼内レンズ
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN105446939B (zh) * 2015-12-04 2019-02-26 上海兆芯集成电路有限公司 由装置端推核心入队列的装置

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803143A (en) 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (en) 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamine dervivatives and acid addition salts thereof
GB8912971D0 (en) 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ES2143992T3 (es) 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
EP0755923B1 (en) 1995-01-23 2005-05-04 Daiichi Suntory Pharma Co., Ltd. Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor
EP0907654B1 (en) 1995-11-06 2000-08-02 Dsm N.V. De-esterification process
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
KR20000035880A (ko) 1996-08-27 2000-06-26 이곤 이 버그 도파민 ｄ2 효능제 및 5ｈｔ1ａ 리간드로서의 4-아미노에톡시 인돌
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
CN1721401A (zh) 1999-04-02 2006-01-18 伊科斯公司 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途
AU780725B2 (en) 1999-04-30 2005-04-14 Trustees Of The University Of Pennsylvania, The Spect imaging agents for serotonin transporters
AU6621600A (en) 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
PL355289A1 (en) 1999-10-13 2004-04-05 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
TR200201683T2 (tr) 1999-12-30 2002-12-23 H. Lundbeck A/S İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları
CN1244577C (zh) 1999-12-30 2006-03-08 H.隆德贝克有限公司 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
ATE261958T1 (de) 1999-12-30 2004-04-15 Lundbeck & Co As H Phenylpiperazinyl-derivate
EP1267868B1 (en) 2000-02-29 2007-07-18 MediQuest Therapeutics, Inc. Inhibitors of melanocyte tyrosinase as topical skin lighteners
AU2001258771A1 (en) 2000-05-19 2001-11-26 Takeda Chemical Industries Ltd. -secretase inhibitors
US6455738B1 (en) 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
WO2002015910A1 (en) 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
KR20030059107A (ko) 2000-09-01 2003-07-07 에프엠씨 코포레이션 살충제로서의 이치환된 벤젠
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
US6852816B2 (en) 2000-10-06 2005-02-08 Biocompatibles Uk Limited Zwitterionic polymers
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
BR0115296A (pt) 2000-11-14 2003-09-02 Merck Patent Ges Mit Beschonkt Uso de inibidores de recaptação de sorotonina e agonistas de 5ht1a combinados
AR035521A1 (es) * 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP4187642B2 (ja) * 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
HUP0401924A3 (en) 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
MXPA04006119A (es) 2001-12-21 2004-11-01 Lundbeck & Co As H Derivados aminoindano como inhibidores de la absorcion de la serotonina y de la norepinefrina.
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US7829044B2 (en) 2002-03-04 2010-11-09 Japan Science And Technology Agency Phosphonamides, process for producing the same, and use thereof
CA2480518C (en) 2002-03-29 2016-07-19 Massachusetts Institute Of Technology Light emitting device including semiconductor nanocrystals
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
CN1662496A (zh) 2002-06-19 2005-08-31 先灵公司 大麻素受体激动剂
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
MXPA05002836A (es) 2002-09-17 2005-05-27 Hoffmann La Roche Indoles 2,4-sustituidos y su uso como moduladores 5-ht6.
JP4327091B2 (ja) 2002-09-17 2009-09-09 エフ．ホフマン−ラ ロシュ アーゲー ２，７−置換インドール及び５−ｈｔ６モジュレーターとしてのその使用
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
PL376479A1 (en) * 2002-10-18 2005-12-27 F.Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
US20040137389A1 (en) 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
US7189501B2 (en) 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
EP2267049A1 (en) 2003-02-05 2010-12-29 Biocompatibles UK Limited Block copolymers
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
US7229751B2 (en) 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
PL1701940T3 (pl) * 2003-12-23 2008-11-28 H Lundbeck As Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI
SE528250C2 (sv) 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006098380A1 (ja) 2005-03-15 2006-09-21 Fujifilm Corporation 円盤状化合物を用いた表面処理法、表面処理用（潤滑）組成物及び表面処理された物品

Also Published As

Publication number Publication date
WO2006007843A1 (en) 2006-01-26
CN1972911A (zh) 2007-05-30
PL1771415T3 (pl) 2009-06-30
UA82610C2 (uk) 2008-04-25
MXPA06015201A (es) 2007-03-15
SI1771415T1 (sl) 2009-04-30
KR20070036061A (ko) 2007-04-02
EP1771415B1 (en) 2009-01-07
EA011418B1 (ru) 2009-02-27
RS50804B (sr) 2010-08-31
PT1771415E (pt) 2009-03-16
CY1108942T1 (el) 2014-07-02
DK1771415T3 (da) 2009-02-23
EP1771415A1 (en) 2007-04-11
NO20066010L (no) 2006-12-27
US20080027074A1 (en) 2008-01-31
CA2570805A1 (en) 2006-01-26
AR052308A1 (es) 2007-03-14
CA2570805C (en) 2010-08-24
DE602005012272D1 (de) 2009-02-26
JP4865710B2 (ja) 2012-02-01
ZA200610162B (en) 2008-06-25
JP2008506640A (ja) 2008-03-06
ATE420071T1 (de) 2009-01-15
US7678800B2 (en) 2010-03-16
ES2317266T3 (es) 2009-04-16
BRPI0512073A (pt) 2008-02-06
EA200602180A1 (ru) 2007-04-27
IL179924A0 (en) 2007-05-15
AU2005263324A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
HRP20090112T3 (hr) Derivati 2-(1 h-indonilsulfanil)-arila za primjenu u liječenju afektivnih poremećaja, bolova, poremećaja pažnje i hiperaktivnosti (adhd) i stres urinarne inkontinencije
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
MXJL06000006A (es) Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
MY129796A (en) Novel anti-inflammatory androstane derivatives
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
SE0302487D0 (sv) Novel compounds
GEP20084360B (en) Substituted quinoline compounds
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0202463D0 (sv) Novel compounds
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
NO20062453L (no) Tiozolidinoner, fremstilling og anvendelse derav som legemidler
SE0302324D0 (sv) Novel compounds
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
GEP20135883B (en) Iminopyridine derivatives and usage thereof
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
HUP0100621A2 (hu) Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények
SE0302756D0 (sv) Novel Compounds
DK1532131T3 (da) Motilid-forbindelser
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer